UCSF begins clinical trial of Halozyme’s PEGPH20 to treat pancreatic cancer patients
To be conducted within the UCSF Helen Diller Family Comprehensive Cancer Center, the Phase II trial will investigate PEGPH20 in combination with gemcitabine and nab-paclitaxel (ABRAXANE) in patients